Advent Life Sciences Announces Appointment of Alan Walts as Venture Partner

Press Release:
Advent Life Sciences Announces Appointment of Alan Walts as Venture Partner
 
Press Release:
9th January 2014, London: - Advent Life Sciences announced today the appointment of Alan Walts as a Venture Partner.  Alan brings 27 years of biotech industry experience in corporate venture capital, business development, research and development, and general management at Genzyme Corporation.  He most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi-Genzyme BioVentures), where he was responsible for identifying and managing a portfolio of investments. 

Alan earlier led business and corporate development activities in Genzyme’s Therapeutics business, where he initiated and executed a number of transactions and new business initiatives that led to several innovative marketed products.  Alan’s roles at Genzyme also included President of Genzyme Pharmaceuticals and head of chemistry and biopolymer research. 

Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School in 1993.

- Ends -

 
About Advent Life Sciences:
Advent Life Sciences is the dedicated Life Sciences team at Advent Venture Partners, one of Europe’s best established venture capital firms.  Advent Life Sciences predominantly founds and invests in early-stage life sciences companies in the UK, Europe and the US, that have a first- or best-in-class approach. Recent investments include:  UniQure (formerly AMT), a company that recently obtained the first EMA approval for a gene therapy product; EUSA Pharma, a speciality pharmaceutical company that obtained a BLA approval for its lead product Erwinase® and was subsequently acquired by Jazz Pharmaceuticals; Algeta (OSE: ALGETA), an oncology company that obtained FDA and EMA approval for Xofigo®, a treatment for bone metastases and disseminated tumours; Avila Therapeutics, a biotechnology company developing targeted covalent drugs acquired by Celgene; and CN Creative Ltd, a medical device company acquired by BAT.
 
For more information, please contact:
 
Melanie McIntosh
Advent Life Sciences
Phone: +44 (0) 20 7932 2100
Email: melanie.mcintosh@adventventures.com
www.adventventures.com

 

Back